MEDINCELL news, videos and press releases
For more news please use our advanced search feature.
MEDINCELL - More news...
MEDINCELL - More news...
- Medincell Strengthens its Board of Directors to Support its Growth
- Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA
- Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
- Medincell Announces Successful c.€43 Million Global Offering
- Medincell Launches a Global Offering for Approximately 10% of Its Share Capital
- Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
- Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
- The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement
- Medincell: UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
- Medincell: Publication of the 2025 Financial Calendar
- Medincell to Join the Euronext SBF 120 Index
- Medincell to Join the Euronext SBF 120 Index
- Medincell Publishes Its Consolidated Half-year Financial Results
- Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
- Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
- Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024
- MedinCell and the European Investment Bank (EIB) Have Replaced a Financial Covenant of Their Ongoing Loan Agreement to Better Fit with MedinCell Business Model
- MedinCell: Participation Terms in the Combined General Meeting
- MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
- MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
- MedinCell has Received the Last Tranche of €10m from the European Investment Bank (EIB) Loan
- MedinCell Announces the Availability of Its 2022-23 Universal Registration Document Including the Annual Financial Report
- Half-Year Liquidity Contract Statement for MEDINCELL
- MedinCell Announces Its Full Year Financial Results
- MedinCell: Videoconference and Publication of Financial Results for 2022-2023 on June 26th, 2023
- MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023
- MedinCell: Phase 1 Data of mdc-TJK Investigational Long-Acting Injectable of Olanzapine for Schizophrenia Patients, Exhibited Favorable Characteristics of an Extended-Release Profile
- MedinCell Announces the Successful Pricing of Its Global Offering and Raises €25 million
- MedinCell launches a Global Offering for approximately 25 million euros
- MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
